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ABSTRACT
Introduction: The REGAL (RSV [respiratory
syncytial virus] Evidence—a Geographical
Archive of the Literature) series provides a
comprehensive review of the published
evidence in the field of RSV in Western
countries over the last 20 years. This first of
seven publications covers the epidemiology and
burden of RSV infection.
Methods: A systematic review was undertaken
for articles published between Jan 1, 1995 and Dec
31, 2015 across PubMed, Embase, The Cochrane
Library, and Clinicaltrials.gov. Studies reporting
data for hospital visits/admissions for RSV
infection among children (B18 years of age), as
well as studies reporting RSV-associated
morbidity, mortality, and risk factors were
included. Study quality and strength of evidence
(SOE) were graded using recognized criteria.
Result: 2315 studies were identified of which
98 were included. RSV was associated with
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12–63% of all acute respiratory infections (ARIs)
and 19–81% of all viral ARIs causing
hospitalizations in children (high SOE).
Annual RSV hospitalization (RSVH) rates
increased with decreasing age and varied by a
factor of 2–3 across seasons (high SOE). Studies
were conflicting on whether the incidence of
RSVH has increased, decreased, or remained
stable over the last 20 years (moderate SOE).
Length of hospital stay ranged from 2 to
11 days, with 2–12% of cases requiring
intensive care unit admission (moderate SOE).
Case-fatality rates were\0.5% (moderate SOE).
Risk factors associated with RSVH included:
male sex; age\6 months; birth during the first
half of the RSV season; crowding/siblings; and
day-care exposure (high SOE).
Conclusion: RSV infection remains a major
burden on Western healthcare systems and
has been associated with significant morbidity.
Further studies focusing on the epidemiology of
RSV infection (particularly in the outpatient
setting), the impact of co-infection, better
estimates of case-fatality rates and associated
risk factors (all currently moderate/low SOE) are
needed to determine the true burden of disease.
Funding: Abbvie.
Keywords: Acute respiratory infection;
Bronchiolitis; Burden; Epidemiology; Lower
respiratory tract infection; Respiratory
syncytial virus
INTRODUCTION
Respiratory syncytial virus (RSV) is the most
common cause of infection of the upper and
lower respiratory tract in infants and young
children worldwide and a major public health
burden [1–10]. Globally, there are an estimated
33 million annual cases of RSV-associated lower
respiratory tract infection in children under the
age of 5 years, with at least 3.4 million episodes
necessitating admission to hospital [1].
Although the risk of hospital admission is
higher in known risk groups, such as those
born prematurely, in particular, those with
chronic lung disease (CLD)/bronchopulmonary
dysplasia (BPD), and those with congenital
heart disease (CHD) [11–15], the majority of
severe cases of RSV infection occur among
previously healthy term infants [14, 16].
Severe RSV infection remains a significant
unmet medical need, and reducing the health
burden of RSV has become a priority of the
World Health Organization’s (WHO) BRaVe
(Battle against Respiratory Viruses) initiative
[17, 18]. Part of the research agenda of this
initiative is to define the burden of respiratory
viral infections [18].
Over the last 20 years, there has been a
considerable body of research published on RSV
that has improved our understanding of the
epidemiology in different risk groups, the acute
and long-term burden to children and to
healthcare systems, the underlying infection
process and genetics, as well as preventive and
management strategies. An understanding of
the incidence and complications of RSV disease
is essential for planning strategies to control
RSV infection and to optimize the use of RSV
prophylaxis and future RSV vaccines [19–21].
To provide a comprehensive understanding
on severe RSV disease in infants and children in
Western societies, an expert panel, comprising
Neonatologists, Pediatricians, Pediatric
Infectious Disease Specialists, Pediatric
Cardiologists and Pediatric Pulmonologists
from the United States, Canada and Europe,
undertook an evidence-based search of the
literature which has accumulated over the past
two decades. The primary objective of REGAL
(RSV Evidence—a Geographical Archive of the
Literature) was to carry out a series of systematic
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literature reviews and, then, to assess, quantify,
summarize and grade the evidence base. By
undertaking this review, the current state of the
art in our understanding of RSV was defined as
well as, importantly, gaps in our knowledge and
future areas of research.
This paper represents the first of a series of
seven publications encompassing different areas
of the systematic review and covers in detail the
overall methodology that was followed for each
of the reviews, and summarizes the first topic:
the epidemiology and burden of severe RSV
infection requiring hospitalization among
infants and children in Western societies.
METHODS
Objectives
The primary objective of REGAL was to address
seven specific research questions (Table 1). The
systematic literature reviews undertaken to
answer each of these research questions all
used the same broad methodology, which is
described in detail below.
Search Strategy and Selection Criteria
Following a study protocol with pre-defined
search terms, we conducted a systematic and
comprehensive search of the medical literature
electronically indexed in MEDLINE (PubMed),
Embase and The Cochrane Library. Search
strategies were devised for each systematic
review and combined free-text search terms
with medical subject headings (MeSH). An
important part of the protocol was the
countries to be included. The overall burden of
RSV has been studied in many industrialized
countries, and therefore, to ensure a manageable
volume of publications, only studies conducted
in Western countries were included, which we
defined as the United States, Canada, and
Europe (including Turkey and the Russian
Table 1 REGAL: study questions
1. What is the overall epidemiology and disease burden of severe RSV infection in Western countries, and what are the
associated risk factors for RSVH?
2. What is the predisposition and associated morbidity, long-term sequelae and mortality of preterm infants
(\37 wGA) without CLD/BPD or CHD, overall, and split by gestational age segments, to severe RSV infection, and
what are the risk factors associated with RSVH?
3. What is the predisposition and associated morbidity, long-term sequelae and mortality of infants with underlying
CLD/BPD to severe RSV infection in Western countries?
4. What is the predisposition and associated morbidity, long-term sequelae and mortality of infants with underlying
CHD to severe RSV infection in Western countries?
5. What is the nature, incidence and impact of long-term respiratory morbidity associated with RSVH in infancy in
Western countries, speciﬁcally early and late wheeze?
6. What other groups of infants with underlying medical conditions or chronic diseases are at high risk of RSVH and
associated morbidity?
7. What are the optimal approaches and strategies for the prevention and treatment of severe RSV infection and what
are the future perspectives in this regard?
BPD bronchopulmonary dysplasia, CHD congenital heart disease, CLD chronic lung disease, RSV respiratory syncytial virus,
RSVH RSV hospitalization, wGA weeks’ gestational age
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Federation). The full protocol for the systematic
reviews is available as part of the online
supplement (Supplementary Material 1—
REGAL Protocol). Our search included studies
conducted in children (defined as B18 years)
and published between January 1, 1995 and
December 31, 2015. The target populations for
REGAL included previously healthy term or
preterm children [\37 week gestational age
(wGA)], those with CLD/BPD, CHD, or other
high-risk comorbid conditions (e.g., anatomic
pulmonary abnormalities, neuromuscular
disorders, Down syndrome,
immunodeficiencies and cystic fibrosis) with
‘proven’ or ‘probable’ RSV. Children who had
received immunoprophylaxis with palivizumab
were included.
No language limits were set on the database
searches, with the caveat that English
translations of at least the abstract had to be
available. Since there is not a universal,
standardized definition of severe RSV disease,
for the purposes of this article, we have taken
this to be ‘RSV infection requiring
hospitalization’. Randomized controlled trials,
non-randomized controlled trials, crossover
trials, single-arm studies, cohort studies
(prospective and retrospective), case–control
studies (prospective and retrospective), and
case series were included, as well as published
data from registries and medical databases. We
also searched the database ClinicalTrials.gov,
which provides information on current ongoing
clinical research studies being conducted
around the world. In addition, we
hand-searched online journals and scanned
the reference lists of identified citations and
relevant abstracts presented at key meetings to
find additional relevant publications for each of
the reviews.
Two reviewers (J. Smith and J. Blake)
undertook the search adopting a two-phase
screening process. In Phase 1, the title (Stage
1) and, then, the abstract (Stage 2) of all
identified studies were independently assessed
for their relevance in answering the research
question (details of the reviewers can be found
in the Acknowledgments). The following
short-term outcomes were assessed: incidence
rates of severe RSV infection requiring medical
treatment during the first or subsequent years of
life, RSV hospitalization (RSVH) rates, length of
stay (LOS) in hospital, RSVH-related outcomes
[intensive care unit (ICU) admission, LOS in
ICU, requirement for, and duration of,
mechanical ventilation, non-invasive
ventilation and oxygen], case-fatality rate, and
risk factors for severe RSV infection requiring
hospitalization. The following long-term
outcomes were assessed: subsequent
respiratory disease, including recurrent
wheezing and asthma up to adulthood
(B18 years) following severe RSV infection in
infancy. Other outcomes assessed were the
effectiveness of palivizumab in reducing RSVH
rates and associated morbidity, long-term
sequelae and mortality in different subgroups
of children with or without CLD/BPD, and
future developments in RSV research including
genetic phenotypes and polymorphisms.
All studies marked in Phase 1 as potentially
relevant were then independently assessed at
the full-text level by the same two reviewers for
inclusion (Phase 2). Any disagreements were
resolved after discussion with a third reviewer
(B. Rodgers-Gray) and X. Carbonell-Estrany. The
search results were compiled into a spreadsheet,
including documentation of the reason(s) for
excluding a study. Data were extracted for all
identified articles by one reviewer and
quality-checked by the second reviewer, and a
written report was produced (Supplementary
Material 2—Data Extraction Table). The authors
reviewed the search results and report, made
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any additions and amendments, and all
approved the final list of studies for inclusion.
For each systematic literature review, we fully
documented the inclusion and exclusion
processes using a PRISMA flowchart that
detailed the number of included and excluded
articles.
Data Synthesis
Included publications were graded according to
the Oxford Centre for Evidence-Based Medicine
Levels of Evidence [22, 23]: level 1 evidence
(local and current random sample surveys [or
censuses]); level 2 evidence (systematic review
of surveys that allow matching to local
circumstances); level 3 evidence (local
non-random sample); level 4 evidence (case
series). For randomized, controlled trials, a
quality assessment for each citation was
carried out using the five-point (1 = low
quality; 5 = high quality) Jadad Scale [24]. For
each study, we also conducted a risk of bias
assessment using the RTI Item Bank (score of
1 = very high risk of bias; score of 12 = very
low risk of bias) for observational studies [25]
and the Cochrane Collaboration’s tool for
assessing risk of bias for randomized clinical
trials [26].
METHODS USED FOR CURRENT
STUDY: OVERALL EPIDEMIOLOGY
AND BURDEN OF RSV
The target population for the first systematic
literature review in our series was previously
healthy term children or studies with mixed
populations of term and preterm (\37 wGA)
children and those with comorbidities. We
excluded studies that focused exclusively on
particular subgroups, such as preterm infants
(\37 wGA), those with CLD/BPD or CHD, or
other medical conditions (e.g. Down
syndrome), since this systematic literature
review considers the overall epidemiology and
burden of RSV in infants and children.
However, studies were included if a proportion
of the study population had comorbidities.
In this first systematic literature review, we
sought to answer the following question:
1. What is the overall epidemiology and
disease burden of severe RSV infection in
Western countries, and what are the
associated risk factors for RSVH?
We performed a literature search using the
following combination of search terms and
limits: ‘‘RSV’’ OR ‘‘respiratory syncytial virus’’
AND ‘‘hospitalization’’ AND ‘‘epidemiology’’ OR
‘‘disease burden’’ OR ‘‘burden’’ OR ‘‘risk’’ OR
‘‘risk factor’’ AND ‘‘limits: human, infant aged
up to 1 year; child (unspecified age)’’.
‘‘Bronchiolitis’’ and ‘‘pneumonia’’ were
captured as part of the MeSH terms. It is
recognized that while some relevant articles
might have been missed by the searches, we are
confident that the combined Boolean operators
‘‘AND’’ and ‘‘OR’’ of the key text words and
index terms precisely captured the vast majority
of relevant citations which were pertinent for
this evidence-based review. The short-term
outcomes of interest for this review included
hospitalization rates due to severe RSV, hospital
LOS, ICU admission and LOS, oxygen
requirement, need for and duration of
mechanical ventilation and/or non-invasive
ventilation, case-fatality rates, and risk factors
(including biological, environmental and
social) for severe RSV infection requiring
hospital admission.
Statement of Ethics Compliance
The analysis in this review article is based on
previously published studies and does not
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involve any new studies of human subjects
performed by any of the authors.
RESULTS AND DISCUSSION
Articles Selected
A total of 98 publications were included in the
final review: 90 identified from the database
searches and a further 8 from reference lists/
other sources (Fig. 1). Data extraction tables for
all 98 studies, including evidence grades and
risk of bias assessments, can be found in the
online supplement (Supplementary Material
2—Data Extraction Table).
Incidence of RSV Hospitalization
RSV has been associated with 12–63% of all
acute respiratory infections (ARIs)
[12, 16, 27–40] and 19–81% of viral ARIs
causing hospitalization in infants and children
[41–57] (Table 2). Importantly, while high-risk
groups are particularly vulnerable to severe
infection and are often the focus of study, the
majority (typically [70%) of children
Fig. 1 PRISMA ﬂow diagram: overall epidemiology and
burden of severe respiratory syncytial virus (RSV) infec-
tion. The third reviewer (B. Rodgers-Gray) and X.
Carbonell-Estrany were not required to resolve any
disagreements during the review process
276 Infect Dis Ther (2016) 5:271–298
Table 2 Epidemiology of hospitalizations for RSV-associated bronchiolitis in infants and children




Resch (2002) [57] Austria 1-year prospective study
(1999–2000); single center; all
children\2 years hospitalized with
viral U/LRTIs (included high-risk
children [preterm, CHD])
21%b Term: 7/1000/year
Resch (2000) [56] Austria 4-year retrospective study
(1994–1998); single center; all








Canada 2-year retrospective study
(2008–2010); regional; all
hospitalized children\19 years old
with LRTI and RSV/LRTI
(included high-risk children and





Croatia 11-year retrospective study
(1994–2005); national; all children





Denmark 7-year population-based cohort study
(1997–2003); 6 national registries;
infants B24 months old (included

















NR \6 months: 34/1000/
season
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Table 2 continued






France 3-year prospective study
(2002–2004); single center;
children\16 years old admitted
with an ARI, fever or asthma
80.8%b NR
Weigl (2001) [29] Germany 3-year retrospective study
(1996–1999); city; children
\16 years old admitted with an
ARI
12.1% \2 years: 7.25/1000
Tsolia (2003) [84] Greece 4-year retrospective/prospective
(1997–2000); regional; infants
\12 months old admitted with
bronchiolitis (included high-risk
infants [preterm infants B36 wGA,





Greece 2-year prospective, epidemiological
study (1999–2000); 4 regions;
children B2 years old admitted
with ARI (included healthy
full-term infants and high-risk





Italy 5-year retrospective study
(2009–2014); single center;
children\3 years old admitted
with a viral ARI
54.2% NR
Ferrara (2014) [32] Italy 9-year retrospective study
(2004–2013); single center; infants








\15 years old admitted with an
ARI
34.1% NR
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Table 2 continued






Italy 7-month prospective, surveillance
study (2005–2006); regional;
children\2 years old admitted
with LRTI (included infants born
\36 wGA)
40.9% NR
Medici (2006) [50] Italy 4 year prospective, observational
study (2000–2004); national;
children B4 years old admitted for
an ARI (included previously
healthy term and at-risk [B35
wGA BPD/CLD] infants)
49% NR
Lanari (2002) [33] Italy 6-month prospective, epidemiological
study (1999–2000); multicenter;
children\2 years old admitted for





Netherlands 5-year prospective birth cohort study
(2003–2005 and 2006–2007);
single center; infants\12 months







Netherlands 2-year retrospective cohort study
(2006–2007); single center;
children\18 years old admitted
with an ARI (included preterm




Fjaerli (2004) [7] Norway 8-year retrospective, population-based
study (1993–2000); single center/
region; children\2 years old
admitted with bronchiolitis
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Table 2 continued




Flores (2004) [85] Portugal 2-year prospective study
(2000–2002); single center;
children\3 years old admitted










children B2 years old admitted






Spain 15-year observational, retrospective
survey (1997–2011); included
[98% Spanish hospitals; children








Herva´s (2012) [12] Spain 12-year retrospective study
(1995–2006); single center/region;
children B2 years old admitted
with acute bronchiolitis (included
high-risk children [preterm, CHD,
atelectasis/condensation, urinary
tract infection])
62.7% B2 years: 55/1000a
Garcı´a-Garcı´a
(2012) [42]
Spain 6-year prospective study
(2004–2010); single center;






Spain 1-year prospective study
(2008–2009); region; children
\18 months old admitted with
bronchiolitis
56.4% NR
Calvo (2010) [39] Spain 3-year prospective study
(2005–2008); single center;
children\2 years old admitted
with acute viral bronchiolitis
61.3% NR
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Table 2 continued






Spain 3-year prospective study
(2002–2005); single center;





Spain 2-year retrospective study
(2001–2002); province; children
\2 years old admitted with
bronchiolitis
42.2% \12 months: 40.2/1000/
yearc
Vicente (2003) [6] Spain 4-year retrospective, population-based
study (1996–2000); single center/
province; children\5 years old
admitted with an ARI





Sweden 7-year retrospective study
(2004–2011); regional; children
\5 years old with an RSV infection
(included high-risk children
[wheezy bronchitis, CHD, Down










Sweden 12-year retrospective study
(1987–1998); single center;
children admitted with conﬁrmed








Bicer (2013) [52] Turkey 1-year retrospective cohort study
(2010–2011); single center;





Turkey 1-year study; multicenter; children
B2 years old admitted with LRTI
37.9% 7.8/1000/year
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Table 2 continued







Turkey 2-year prospective, epidemiological
study (2008-2010); multicenter;
children\2 years old with
diagnosis of respiratory failure due
to LRTI (excluded children with
immunodeﬁciency, CF or





UK 2-year prospective, descriptive study
(2002–2003 and 2003–2004);
single center; children\6 years old
presenting with inﬂuenza-like
illness (included high-risk children
[asthma, CHD, BPD, CF, sickle


















UK 3-year retrospective, population-based
study (1996–1999); county;
children\2 years old admitted
with a respiratory illness (included
high-risk children [preterm, BPD/
CLD])
58.8% \2 years: 16.3/1000a
Mu¨ller-Pebody
(2002) [34]
UK 3-year retrospective study
(1995–1998); national; children
\5 years old admitted with LRTI
(included high-risk children
[preterm, BPD/CLD])
17.5% \12 months: 28.3/1000/
year
1–4 years: 1.3/1000/year
Hall (2013) [16] US 5-year prospective, population-based
study (2000–2005); 3 counties;
children\2 years old admitted
with an ARI (included preterm
infants\37 wGA and infants with
comorbid conditions)
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US 4-year serial, cross-sectional analysis of
a nationally representative sample
of children (2000, 2003, 2006,
2009); national; children\2 years
old hospitalized with bronchiolitis
(included high-risk children
[preterm or C1 complex medical
condition])






US 10-year retrospective study
(1997–2006); national; children












Zhou (2012) [49] US 16-year retrospective surveillance
study (1993–2008); 13 states; all
ages including adults admitted with
inﬂuenza or RSV




Garcı´a (2010) [44] US 6-year retrospective study
(2002–2007); single center/region;
children\2 years old admitted
with bronchiolitis (included
high-risk children [prematurity,






Iwane (2004) [45] US 12-month prospective, active,
population-based, surveillance study
(2000–2001); 2 counties; children
\5 years old admitted with an ARI
(included children with chronic
conditions)
20%b \5 years: 3.5/1000/year
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hospitalized with RSV-related ARI/bronchiolitis
had no underlying medical conditions
[14, 16, 44, 56–58]. To put the burden of RSV
into context, in comparison to influenza,
retrospective analyses show that RSV causes up
to 16 times more hospitalizations and
emergency department visits in children aged
\5 years [49, 59, 60].
Hospitalization rates for RSV ARIs increase
with decreasing age, peaking in the first few
months of life [4, 6, 7, 16, 34, 35, 37, 56, 61].
Most retrospective studies have consistently
shown RSVH to be the highest in the first year
of life [7, 49, 56, 61]. In the prospective study by
Hall et al. [16], 1-month-old infants,
consistently, were the most likely to be
hospitalized, almost twice as often as the next
two most at-risk groups: infants \1 month old
and infants 2 months old. Incidence rates for
confirmed RSVH in the first year of life in
healthy term infants may be relatively low at
\1% [51], though around 2% of all infants
including those with comorbidities are included
[61, 62]. More studies in healthy term infants
are required. Overall, studies have found that
between 75% and 90% of infants hospitalized
with RSV were aged B12 months, and between
44% and 83% were aged B6 months
[6, 7, 12, 16, 44, 56, 63–65]. Only a minority
(B5%) of neonatally hospitalized children are
rehospitalized for RSV infection [57, 66, 67].
Annual hospitalization rates for
RSV-associated ARIs in the first year of life
range from 3.2/1000/year [16] to 42.7/1000/
year [37], and decreased with increasing age to
0.6/1000/year [61] to 1.78/1000/year [49] in
children aged 1–4 years (Table 2). The reported
rates of RSVH, however, vary considerably
between studies and across seasons within the
same study.
Incidence of RSV in Emergency
Departments and Outpatient Settings
There are very limited data available on the
incidence and burden of RSV infection
managed on an outpatient basis or in the
emergency department [14, 60]. Available
studies suggest that the outpatient burden of
RSV on healthcare resources has not been fully
recognized by healthcare providers [14]. For
example, a US study reported that only 3% of
Table 2 continued




Leader (2003) [62] US 3-year retrospective study
(1997–2000); national; infants
B12 months old admitted with






ARI acute respiratory infection, BPD bronchopulmonary dysplasia, CF cystic ﬁbrosis, CHD congenital heart disease, CLD
chronic lung disease, GA gestational age, LRTI lower respiratory tract infection, NR not reported, RSV respiratory syncytial
virus, U/LRTI upper or lower respiratory tract infection, wGA weeks’ gestational age
a Overall hospitalization rate during study period
b Virally conﬁrmed ARIs tested
c Bronchiolitis-related hospitalizations
284 Infect Dis Ther (2016) 5:271–298
outpatients with RSV infection received the
diagnosis of RSV-associated illness, as
compared with 45% of inpatients (P\0.001)
[14]. Based on study data, RSV infection was
estimated to result in one of 334
hospitalizations, one of 38 visits to an
emergency department, and one of 13 visits to
a primary care office each year in the US [14].
Another US study estimated that, at a national
level, more children required an emergency
department visit for a RSV infection compared
with an influenza infection (21.5 vs. 10.2 visits
per 1000 children/year, respectively) [60]. The
total estimated number of workdays missed
annually by caregivers of children who
required emergency department care was
716,404 days for RSV infections [60].
Trends in RSV Hospitalization Rates
A number of studies have examined the
national trends in RSVH rates among infants
and children over the past two decades. While
some studies conducted in the United States
[44, 68] and Canada [69] throughout the 1980s
and 1990s and the early 2000s have shown a rise
in RSVH rates, other studies, both in the United
States [70] and in France [71], conducted
between 1998 and 2009, report a decrease in
the incidence rate of bronchiolitis and RSVH.
Further studies in the United States and Europe
report that RSVH rates have remained relatively
stable over similar time periods [7, 35, 72]. A
firm conclusion on long-term time trends is not
possible.
Season-on-season RSVH rates have been
shown to vary by up to a factor of two to
three in the same geographic region [6, 7, 16].
The length and start date of the RSV season can
also vary from year to year [50, 73–75]. In
temperate, northern hemisphere countries the
season typically starts in October or November,
peaks in December or February, and finishes in
March or April [4, 6, 7, 16, 44, 50, 63]. Changes
in surveillance programs, testing rates, the RSV
tests used, and admission criteria within and
between countries, as well as variations in
disease severity and levels of circulating virus,
all contribute to the varying incidences
reported over time and highlight the need for
rigorous, uniform, and ongoing data collection.
Co-infections
RSV has a high rate of co-infection with other
respiratory viruses with a similar seasonal
pattern, such as influenza, rhinovirus (RV),
human metapneumovirus (hMPV) and human
bocavirus (HBoV) [28, 41, 76, 77], and also with
bacterial pathogens [78, 79]. Co-infections,
most commonly dual infections, have been
reported to occur in up to 50% of
RSV-hospitalized children, [76, 78, 79]. In a
prospective study of 2525 children aged
\14 years by Calvo et al. [76], 599 RSV single
infections and 326 RSV multiple infections were
detected. The most frequent dual infection was
between RSV and RV (120 episodes) and the
second between RSV and HBoV (60 episodes).
Other dual RSV infections included 3 episodes
of RSV and hMPV and 11 episodes of RSV and
influenza [76].
Co-infections represent a major confounder
in burden of disease analyses of RSV infection
[78, 79]. At present, the clinical data available
on co-infection, in terms of both the number of
viruses involved and the severity of the
condition, are variable and even, at times,
contradictory [80]. Some studies have reported
that multiple infections were associated with
more severe disease and longer hospital stays
than with single RSV infections [42, 76, 81].
Calvo et al. [76] found that hospitalization was
longer for both RSV simple and RSV and HBoV
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co-infection, lasting about 1 day (4.7 vs.
3.8 days; P\0.001) longer than in simple
HBoV infections. In contrast, Martinez-Roig
et al. [80] found an inverse relationship
between the number of viruses detected in
nasopharyngeal aspirate, the need for oxygen
therapy and hospitalization days. In this
prospective study of 463 pediatric patients
aged between 7 days and 15 years hospitalized
with respiratory infections (none with risk
factors for respiratory diseases), the most
common co-infections were RV and RSV-B (10
cases) and RSV-A and RSV-B (5 cases).
Hospitalization decreased with greater number
of viruses (P\0.001). Oxygen therapy was
required by 26.75% (1 virus was detected in
55.34% of cases). A larger number of viruses
resulted in less need for oxygen (P\0.001). Ten
cases required mechanical ventilation, 4
patients with bacterial co-infection and 5 with
viral co-infection (P = 0.69). The most common
co-infections were RV and RSV-B (10 cases) and
RSV-A and RSV-B (5 cases) [80]. Findings from
an earlier Canadian study of 742 children
suspected to have a respiratory illness (33%
with a comorbidity) support equivalent disease
severity between single virus infection and virus
co-infection [82]. In multivariable analysis,
virus co-infection did not affect admission to
hospital after adjustment for age and the
presence of underlying conditions [82].
Morbidity and Mortality Associated
with Severe RSV Infection
Morbidity
Severe RSV infection in infants and children is
associated with substantial morbidity and
constitutes a considerable burden on
healthcare systems [83]. Kristensen et al. [83]
showed that, compared with infants without
predisposing conditions (aged \6 months),
infants with predisposing conditions were
hospitalized longer (median 5 vs. 9 days;
P\0.001) and were treated longer with
continuous positive airway pressure (CPAP)
(median 4 vs. 7 days; P\0.001) and
supplemental oxygen (median 3 vs. 5 days;
P = 0.05). In term infants without predisposing
conditions, age was a predictor of disease
severity. Age correlated inversely with duration
of oxygen therapy (P\0.02), and infants
treated with oxygen or CPAP were significantly
younger than infants who did not receive
respiratory support (oxygen: median age, 52
vs. 91 days; P\0.001; CPAP: median age, 51 vs.
90 days; P = 0.001) [83]. Mu¨ller-Pebody et al.
[34] observed that hospital LOS was
significantly higher (P\0.001) in high-risk
children aged \1 year and in those aged
1–4 years. While Gijtenbeek et al. [88]
observed higher hospitalization rates for
confirmed RSV infection among preterm
infants (32–36 wGA) than full-term infants,
disease severity, length of hospitalization and
the use of mechanical ventilation and oxygen
were similar between gestational groups
(Table 3).
Studies have shown that RSV ARI is associated
with more severe disease than non-RSV ARI,
resulting in a significant impact on healthcare
resource utilization [12, 44, 57]. On average,
infants spend 2–11 days in hospital for RSV ARIs,
with around 2–12% being admitted to ICU
(Table 3) [4, 6, 7, 12, 27, 29, 34, 39, 41, 44,
56, 57, 61–64, 70, 84, 87, 88]. Vicente et al. [6]
reported that infants younger than 6 months had
the longest duration of hospital stay. Perhaps
unsurprisingly, different geographic regions have
varying criteria for admission to hospital and
subsequent management [89, 90], which can
make comparisons of disease severity difficult.
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Nosocomial RSV Infection
There are limited published data on the
epidemiology of nosocomial RSV infection,
but in infants with comorbidities, it often
follows a severe course of disease, sometimes
resulting in mortality [11]. Typically,
nosocomial RSV infection occurs at a low rate
(0.4–6%) [83, 92, 93]. A recent study conducted
in 44 neonatal ICUs in Turkey reported a higher
rate of nosocomial infection in newborns
(9.6%) [94]. Nosocomial RSV infection was
shown to be more severe than
community-acquired RSV in a prospective,
multicenter, surveillance study undertaken in
Germany over 6 consecutive seasons
(1999–2005) [93]. The median LOS was 72 days
[interquartile range (IQR) 31–131] for
nosocomial RSV infection compared with
7 days (IQR 4–10) for community-acquired
RSV (P\0.001). Significantly more children
were admitted to ICU (52% vs. 9%,
respectively; P\0.001) and required
mechanical ventilation (56.7% vs. 12.6%;
P\0.001) [93].
Case-Fatality Rates
The Global Burden of Disease study estimated
that RSV accounted for 1.6% of deaths worldwide
in 2010 [95]. Available data from the published
literature suggest that the mortality rate for RSV
is low in the West (typically \0.5%)
[4, 7, 12, 44, 56, 57, 63–65, 96], whereas higher
rates have been reported in low- and
middle-income countries [97, 98]. Despite
advances in neonatal care, rates of mortality
have been shown to remain relatively stable over
time. A study in the United States reported a
case-fatality rate for bronchiolitis-associated
deaths of infants aged \1 year of 2.2/100,000
live births in 1979 vs. 2.4/100,000 in 1997 [99]. In
a recent 15-year study in Spain, the case-fatality
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Table 4 Reported risk factors for severe RSV disease requiring hospitalization in otherwise healthy term and mixed
populations of children
Independent risk factors for severe RSV infection requiring hospitalization
Presence of older sibling [2, 108]
Birth in proximity to RSV season [16, 109, 110]
Low birth weight [108, 110]
Birth order [33, 109]
Male sex [108]
Young age (\6 months) [14, 16, 27, 100]
Exposure to smoking [86, 101, 108]
Maternal age [110]
Suburban residence [110]
Other risk factors associated with RSV hospitalization
Vitamin D deﬁciency [111]
Family history of atopy/atopic diagnosis [101, 112, 113]
Climatic factors and air pollution [114–116]
High altitude above 2500 m [104]
Socioeconomic status/parental education [117]
Delivery by cesarean section [105]
Level of evidencea
Key statements/ﬁndings
In western countries, RSV has been associated with 12–63% of all ARIs and 19–81% of viral ARIs
causing hospitalization in children
1
Annual hospitalization rates for RSV-associated ARIs ranged from 3.2/1000 children to 42.7/1000
in the ﬁrst year of life, and decreased with decreasing age to 0.6/1000–1.78/1000 in children 1–4 years
1
Longitudinal studies have reported varying annual incidences of RSVH over time: some have
reported an increase, some a decrease, and others relative stability
2
RSV co-infections are frequent (bacterial and viral co-infections have been reported in up to
50% of patients hospitalized with severe RSV ARI). However, the relationship with severity of
disease is not clear
1
Infants spend an average of 2–11 days in hospital for RSV ARIs, around 2–12% are admitted to the ICU,
and the mortality rate is\0.5% and limited to children with severe comorbidity
1/2
A number of risk factors have been independently associated with an increased risk for severe
RSV disease in children, including: male sex; age\6 months; birth during the ﬁrst half of the
RSV season; crowding/siblings; and day-care exposure
1
Key areas for research
The current evidence base likely underestimates the true epidemiology and burden of severe RSV infection, particularly, the burden related to
outpatient and emergency department visits requires further study
The impact of co-infections on the severity of RSV infections requires further deﬁnition and study
Mortality rates are mainly based on excess mortality estimates during the RSV season in a few studies. Reﬁning global mortality estimates and
deﬁning associated risk factors require further study
Geographical differences in RSV epidemiology need to be deﬁned
ARI acute respiratory infection, ICU intensive care unit, RSVH respiratory syncytial virus hospitalization
a Level 1: local and current random sample surveys (or censuses); Level 2: systematic review of surveys that allow matching to local
circumstances; Level 3: local non-random sample; Level 4: case series [22]
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aged 1 year to 0.18% in children aged 4 years [4].
In several studies, the case-fatality rate was
higher among high-risk children, including
those with BPD/CLD, CHD and
immunodeficiency [4, 7, 11, 34].
Risk Factors for RSV Hospitalization
Several important independent risk factors for
RSV hospitalization have been identified,
including male gender, birth in proximity to
RSV season, history of prematurity and tobacco
smoke exposure (Table 4). Age, in particular, has
been found to be a significant predictor in the
severity of infection and RSV hospitalization,
with the youngest age groups (\6 months) more
frequently hospitalized for a RSV infection
[14, 16, 27, 100, 101]. In contrast, some risk
factors, such as breastfeeding, have been found
to be protective [33, 102]. While the
predominance of severe RSV bronchiolitis in
boys compared to girls is well known, its
mechanism is not yet understood [103]. A
study found that the interleukin-9 genetic
polymorphism (rs2069885) has an opposite
effect on the risk of severe RSV bronchiolitis in
boys and girls [103]. Some lesser known risk
factors reported in the literature include high
altitude above 2500 m [104], maternal atopy
[101] and delivery by cesarean section [105].
Black and aboriginal race has also been shown
in some studies to be a risk factor for severe
disease [14, 65, 90, 101, 106], but not in others
[16, 35, 107]. The reasons for these racial
disparities, however, remain unclear, but may
relate to social factors. Risk factors for
RSV-related mortality have not been well
described. Insights into risk factors that
predispose infants to severe RSV infection and
subsequent hospitalization are important to
identify strategies to prevent infection, as well
as to inform guidelines for palivizumab
prophylaxis.
Limitations
There are a few key limitations when
considering this review. With a remit to cover
20 years of study and research into the
epidemiology and burden of RSV, it is
recognized that improvements and changes in
medical practice over time would influence the
findings and conclusions drawn. The
availability, type, and level of diagnostic
testing for RSV undertaken over the review
period is particularly relevant. Older studies—if
any—predominantly used rapid antigen testing,
shell vial culture, and viral culture, which are
generally less sensitive than current PCR
(polymerase chain reaction)-based assays. As
described above, some studies, particularly the
older ones, tended to describe the epidemiology
and burden of bronchiolitis or ARIs without a
totally accurate measure of how much of that
burden or any additional burden related to RSV.
We consider that there is a really important
economical impact of RSV infection on
emergency departments and outpatients, on
co-infections, and on RSV-specific mortality
rates. Unfortunately, there are also limited
economical data of outpatient RSV economical
burden For this reason, this review may
underestimate the true burden of RSV.
CONCLUSIONS
Despite the availability of current preventative
measures, the findings of this review confirm
that RSVH still represents a large burden of
disease in Western countries since it is
associated with significant morbidity. Further
studies focused on the epidemiology and the
incidences of RSV ARIs to determine the true
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burden of disease, particularly in the outpatient
setting, are needed. Well-coordinated
surveillance programs within and across
Western countries involving centers and
hospitals with robust electronic medical
records systems for patient identification and
that test a high proportion of hospitalized
children or visiting outpatients with
respiratory illness for RSV, would be the ideal.
Also, the development of more effective
preventive strategies in high-risk children, as
well as in healthy populations, is essential to
reduce the overall burden of RSV ARI, which
will be the focus of a subsequent paper in the
REGAL series.
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